Chemotherapy-induced peripheral neuropathy - Epidemiology Forecast - 2032

Key Highlights:

• Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent, dose-dependent complication of anticancer drugs, including platinum, taxanes, epothilones, vinca alkaloids, and newer agents, such as bortezomib. It leads to dose reduction or discontinuation of treatment and decreases the quality of life of cancer survivors.
• Chemotherapy-induced peripheral neuropathy presents clinically as sensory, motor, and sometimes autonomic function deficits. Sensory disturbances range from mild tingling to spontaneous burning pain and hypersensitivity to stimuli. These symptoms often affect both hands and feet and may spread into a 'glove/stocking' distribution. Symptoms are usually symmetrical distally but may be more severe unilaterally. Although dependent on the specific agent, the feet are often affected first.
• DelveInsight estimates that in 2022, the highest number of incident cases of chemotherapy-induced peripheral neuropathy were observed in the United States among the 7MM.
• The EU4 and the UK accounted for ~630,000 incident cases of chemotherapy-induced peripheral neuropathy in 2022. Among EU4 and the UK, Germany had the highest number of chemotherapy-induced peripheral neuropathy cases, i.e., ~175,000 cases in 2022.

DelveInsight's "Chemotherapy-induced Peripheral Neuropathy (CIPN) - Epidemiology Forecast - 2032" report delivers an in-depth understanding of the chemotherapy-induced peripheral neuropathy, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2019-2032

Chemotherapy-induced Peripheral Neuropathy (CIPN) Understanding and Diagnostic Algorithm

Chemotherapy-induced Peripheral Neuropathy (CIPN) Overview

Anticancer medications like platinum, taxanes, epothilones, vinca alkaloids, and newer treatments like bortezomib frequently cause dose-dependent side effects. It results in dose reduction or therapy termination and lowers cancer survivors' quality of life; 20% of patients receiving conventional chemotherapy dosages and nearly 100% of those receiving high doses develop chemotherapy-induced peripheral neuropathy.

Clinical symptoms of chemotherapy-induced peripheral neuropathy include sensory, motor, and occasionally autonomic function impairments. Sensory disturbances can range from a slight tingling sensation to a scorching ache that appears out of nowhere and hypersensitivity to stimuli. These symptoms may expand into a "glove/stocking" distribution and frequently involve both hands and feet. Although they may be more severe unilaterally, symptoms are often symmetrical distally. Regardless of the exact agent, the feet are frequently the first to experience symptoms.

Chemotherapy-induced Peripheral Neuropathy (CIPN) Diagnosis

Chemotherapy-induced peripheral neuropathy, a severe treatment-induced toxicity, can restrict function, degrade quality of life, and, in some circumstances, lessen the likelihood of a successful recovery when chemotherapy doses must be lowered. As more neurotoxic substances are developed, and individuals live longer with the effects of neuropathy, the prevalence of this disorder is rising.

People at greatest risk for chemotherapy-induced peripheral neuropathy are believed to include those with comorbid conditions known to contribute to neuropathy, including diabetes, obesity, and HIV. Pharmacogenetic profiling of genetic polymorphisms has been conducted to identify susceptibility to chemotherapy-induced peripheral neuropathy based on genetic polymorphisms. For example, polymorphisms in the CYP2C8 and CYP3A5 genes that encode for paclitaxel-metabolizing enzymes were found to be associated with chemotherapy-induced peripheral neuropathy. Although pharmacogenetic profiling may one day identify patients at greater risk for severe chemotherapy-induced peripheral neuropathy, the data so far are insufficient to draw any definitive conclusions.

Further details related to diagnosis are provided in the report…

Chemotherapy-induced Peripheral Neuropathy (CIPN) Epidemiology

The Chemotherapy-induced Peripheral Neuropathy (CIPN) epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Incident Population of Chemotherapy-induced Peripheral Neuropathy (CIPN), Severity-Specific Incident Population of Chemotherapy-induced Peripheral Neuropathy (CIPN), Incident Population of Chemotherapy-induced Peripheral Neuropathy (CIPN) by Chemotherapeutic Agents, and Incident Population of Chemotherapy-induced Peripheral Neuropathy (CIPN) by Cancer Type in the 7MM covering the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2019 to 2032.

• The total incident population of chemotherapy-induced peripheral neuropathy in the 7MM was ~1,619,000 in 2022.
• Among the European countries, Germany had the highest incident population of chemotherapy-induced peripheral neuropathy, with ~175,000 cases, followed by France, which had ~131,500 incident cases in 2022. On the other hand, Spain had the lowest incident population of chemotherapy-induced peripheral neuropathy, with ~79,000 cases in 2022. Japan had ~310,000 incident cases of chemotherapy-induced peripheral neuropathy in 2022.
• In the US, ~321,000 cases of chemotherapy-induced peripheral neuropathy were caused by chemotherapy with platinum agents in 2022.
• In terms of severity, most patients have been diagnosed with moderate severity. This was followed by mild severity; the least number was observed for severe cases.
• Most chemotherapy-induced peripheral neuropathy cases are caused by platinum-based chemotherapeutic agents followed by taxane agents. The fewest cases were observed with other chemotherapeutic agents (except platinum, taxane, and vinca alkaloid).

Scope of the Report:

• The report covers a segment of key events, an executive summary, and a descriptive overview of chemotherapy-induced peripheral neuropathy, explaining its causes, signs and symptoms, pathogenesis, and diagnosis.
• Comprehensive insight into the country-wise epidemiology segments and forecasts, the future growth potential of cases, and insights on disease prognosis have been provided.
• Patient stratification based on severity-specific cases, chemotherapeutic agent-specific cases, and cancer type-specific cases is an inclusion.
• A detailed review of current challenges in establishing the diagnosis.

Chemotherapy-induced Peripheral Neuropathy (CIPN) Report Insights

• Chemotherapy-induced Peripheral Neuropathy (CIPN) Patient Population
• Severity-wise, Chemotherapeutic agent-wise, and Cancer type-wise Patient Population
• Country-wise Epidemiology Distribution

Chemotherapy-induced Peripheral Neuropathy (CIPN) Report Key Strengths

• Ten years Forecast
• The 7MM Coverage
• Chemotherapy-induced Peripheral Neuropathy Epidemiology Segmentation

Chemotherapy-induced Peripheral Neuropathy (CIPN) Report Assessment

• Epidemiology Segmentation
• Current Diagnostic Practices

Key Questions

Epidemiology Insights

• What are the disease risks and burdens of Chemotherapy-induced peripheral neuropathy? What will be the growth opportunities across the 7MM with respect to the patient population of Chemotherapy-induced peripheral neuropathy?
• What is the historical and forecasted Chemotherapy-induced peripheral neuropathy patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Which chemotherapeutic agent is the largest contributor to the Chemotherapy-induced peripheral neuropathy patient pool?
• Which cancer type contributes more to Chemotherapy-induced peripheral neuropathy cases in the 7MM?
• Which severity has the most number of Chemotherapy-induced peripheral neuropathy?

Reasons to Buy:

• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the change in Chemotherapy-induced peripheral neuropathy incident cases in varying geographies over the coming years.
• A detailed overview of severity-specific, chemotherapeutic agent-specific, and cancer-type-specific Chemotherapy-induced peripheral neuropathy cases is included.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis, patient prognosis, and treatment-eligible patient pool.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.